Deoks

At first glance, Merck’s new cancer-drug deal looks like a $2.13 billion bet. Then you notice the upfront payment: $400 million.

So what does the other $1.73 billion mean? It is not a second check waiting to be cashed. It is potential future money tied to milestones that may or may not happen.

Merck has already closed an exclusive worldwide license for SPR2015, an experimental KRAS G12D drug. But the program is still preclinical, which puts a lot of distance between a promising lab result and a medicine patients can actually use.

That gap—not the headline number alone—is the part worth watching.

Previous Tech(EN) post: Northern Star Rejected Gold Fields’ A$38.7B Proposal—Why Its Value Moved — another look at the difference between a headline transaction value and what it may mean in practice.

Key Takeaways

The $2.13 billion figure is the maximum potential total, including a $400 million upfront payment and up to about $1.73 billion in contingent future milestones.
Merck & Co. (NYSE: MRK) has exclusive worldwide rights to develop, manufacture and commercialize SPR2015; the transaction is already closed.
SPR2015 is an oral, preclinical KRAS G12D (ON) molecular-glue inhibitor. Reported cell and mouse-model activity is not evidence of benefit or safety in people.
Merck says the $400 million upfront will be recorded as a third-quarter 2026 pre-tax charge, approximately $0.13 per share.

Original diagram of Merck’s SPR2015 license terms: $400 million upfront plus up to about $1.73 billion in contingent milestones equals $2.13 billion maximum potential value; the candidate remains preclinical with no human data disclosed. — The $2.13 billion headline includes the $400 million upfront payment; the additional potential value depends on future milestones.

Why is a $2.13 billion deal starting with $400 million?

Because the two figures describe different things. Merck says SciBrunch will receive $400 million upfront and is eligible for additional payments tied to certain development, commercialization and other milestones. Add those conditional payments together with the upfront and the agreement could reach $2.13 billion in aggregate value.

That leaves roughly $1.73 billion beyond the upfront—but the companies have not disclosed the individual milestone amounts, their timing, or the likelihood of reaching them. So the headline is a ceiling under the announced terms, not cash Merck has already paid, a guaranteed future bill, or a probability-adjusted valuation. The arithmetic is simple; the path to earning those milestones is not.

The agreement has closed, and it gives Merck exclusive global rights to develop, manufacture and commercialize SPR2015. That is a license to pursue the program, not an acquisition of SciBrunch. SciBrunch is privately held, so it is not a listed-stock proxy for the deal.

SPR2015 is still a science bet, not a clinical asset

Merck describes SPR2015 as an investigational oral inhibitor of KRAS G12D in its active, or “ON,” state, using a molecular-glue approach. The company reports activity in KRAS G12D-mutant cell lines and antitumor activity in cell-derived and patient-derived xenograft models. Those findings are preclinical: they come from laboratory and animal models, not from patients.

An AACR abstract authored by SciBrunch reported a 64.7% objective response rate and a 94.1% disease control rate across colorectal-cancer xenograft models. Those percentages describe mouse models, not clinical response rates. They do not tell us whether people can take a useful dose safely, whether tumors will respond, or how durable any response might be.

As of Merck’s September 28 announcement, SPR2015 remained preclinical, and the sources checked disclose no human safety or efficacy data. SciBrunch had previously said it expected to advance the program toward a Phase 1 study by the end of 2026; that was a company expectation in an earlier abstract, not confirmation that a trial has started. There is no evidence here of clinical benefit or regulatory approval.

What Merck gets—and what it has to prove

For Merck & Co. (NYSE: MRK), the direct business path is clear at the first step: the company secures rights to a new oncology program and records the $400 million upfront as a third-quarter pre-tax charge, which Merck estimates at about $0.13 per share. The release confirms those terms; it does not provide a probability-weighted sales forecast or a detailed future R&D budget for SPR2015.

There is a broader pipeline context, too. Merck’s 2025 Form 10-K says Keytruda represented 49% of total 2025 sales and notes that U.S. biosimilar competition could begin in December 2028 after the primary compound patent expires. That helps explain why investors watch oncology pipeline replenishment. It does not make SPR2015 a replacement for Keytruda: the drug is preclinical, and its timing, success and commercial potential remain unknown.

Revolution Medicines (NASDAQ: RVMD) is useful only as an independent view of the crowded KRAS G12D field. It is not part of the Merck–SciBrunch agreement, does not receive any of its payments and is not a confirmed beneficiary. Its separate candidate zoldonrasib has entered Phase 3 studies, according to the company. That difference in disclosed stage is relevant landscape context, but the programs, mechanisms and trial populations are not directly comparable—and their efficacy should not be ranked from separate studies.

What investors can watch next

The next useful signals are not another large headline number. They are confirmation of an IND or first-in-human trial, the timing and design of that study, and eventually human data on dose, safety, target engagement and activity by mutation and tumor type. Any later disclosure of milestone terms, R&D spending or changes to financial guidance would also help clarify the economic commitment.

The counterpoint is worth keeping in view: a large upfront payment can reflect strategic conviction and a desire to secure early access to a promising program. But paying for a license is not the same as validating a drug. The central uncertainty remains whether the preclinical signal can translate into a safe and effective treatment for people.

This is industry and company context, not a recommendation to buy or sell MRK or RVMD shares.

Appendix: What does “KRAS G12D (ON)” mean?

KRAS G12D refers to a specific mutation in the KRAS protein. “ON” describes its active state; Merck identifies SPR2015 as an inhibitor of that active-state target. The label alone does not establish how well the drug works in people or whether it will be approved.

Sources

Information checked September 29, 2026. Deal terms and preclinical findings are based on company and abstract disclosures; future development, milestone payments, approval and commercial results are uncertain.

Merck’s $2.13B SciBrunch Deal: Why Is the Upfront $400M?